Recurrent BRAF mutations in Langerhans cell histiocytosis
Open Access
- 16 September 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (11), 1919-1923
- https://doi.org/10.1182/blood-2010-04-279083
Abstract
Langerhans cell histiocytosis (LCH) has a broad spectrum of clinical behaviors; some cases are self-limited, whereas others involve multiple organs and cause significant mortality. Although Langerhans cells in LCH are clonal, their benign morphology and their lack (to date) of reported recurrent genomic abnormalities have suggested that LCH may not be a neoplasm. Here, using 2 orthogonal technologies for detecting cancer-associated mutations in formalin-fixed, paraffin-embedded material, we identified the oncogenic BRAF V600E mutation in 35 of 61 archived specimens (57%). TP53 and MET mutations were also observed in one sample each. BRAF V600E tended to appear in younger patients but was not associated with disease site or stage. Langerhans cells stained for phospho-mitogen–activated protein kinase kinase (phospho-MEK) and phospho-extracellular signal-regulated kinase (phospho-ERK) regardless of mutation status. High prevalence, recurrent BRAF mutations in LCH indicate that it is a neoplastic disease that may respond to RAF pathway inhibitors.Keywords
This publication has 20 references indexed in Scilit:
- Profiling Critical Cancer Gene Mutations in Clinical Tumor SamplesPLOS ONE, 2009
- Polyclonality of BRAF Mutations in Acquired Melanocytic NeviJNCI Journal of the National Cancer Institute, 2009
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway SuppressionCancer Research, 2009
- Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic AstrocytomasCancer Research, 2008
- BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomasJCI Insight, 2008
- Spontaneous Regression of Langerhans Cell Histiocytosis in a Neonate With Multiple Bony LesionsJournal of Pediatric Hematology/Oncology, 2008
- BRAFE600 in benign and malignant human tumoursOncogene, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- BRAFE600-associated senescence-like cell cycle arrest of human naeviNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002